SCNI
Scinai Immunotherapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.72
−3.80%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.73
From 52W high−95.21%
Volume107589.00
Market cap$979466.43
P/E (TTM)—
P/S (TTM)0.7x
Div yield—
Key dataOct 19, 2026
Open
$0.73
From 52W high
−95.21%
Volume
107589.00
Market cap
$979466.43
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
P/E (TTM)
—
RSI (14)
27.7
MomentumView details →
1D Return
−3.80%
YTD Return
−89.90%
SummaryUpdated Jun 1, 2026
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is a development-stage biopharmaceutical company founded in 2003 and headquartered in Jerusalem, Israel. Originally incorporated as BiondVax Pharmaceuticals Ltd., the company rebranded to its current name in September 2023. Scinai went public in 2015 and focuses on developing innovative therapeutic solutions for infectious diseases, autoimmune conditions, and other medical conditions. The company operates through two primary business segments: research and development of proprietary nanobody therapeutics, and contract development and manufacturing organization (CDMO) services for other biotechnology companies.
Similar companies
Latest newsMore news →
Scinai Immunotherapeutics entered into a securities purchase agreement with an existing institutional investor to sell 2,458,334 ADSs or pre-funded warrants, together with Series A-1 warrants to purchase up to 3,687,501 ADSs.6d agoScinai Immunotherapeutics regained compliance with Nasdaq Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00, closing the minimum bid price matter.29d ago